BACKGROUND: Pemetrexed and docetaxel are established therapies in second line non-
small cell lung cancer (NSCLC). Comparative data, concerning the two agents in the …

Background In a phase III study, maintenance pemetrexed showed superior survival over
placebo (PARAMOUNT) for patients with advanced non-squamous non-small cell lung …

PL-5 A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell
lung cancer (NSCLC) who were previously treated with chemotherapy × Close The Infona …

The safety and effectiveness of pemetrexed (PEM) in patients with non-small cell lung
cancer (NSCLC) were reviewed using data from post-marketing surveillance. Among 699 …

Background Pemetrexed is a novel folic acid antagonist with multiple targets, which has
been widely used in the treatment of non-small cell lung cancer (NSCLC). The objective of …

A randomized Phase III trial tested the efficacy of pemetrexed as maintenance treatment in
patients with advanced non-small-cell lung cancer (NSCLC) who were without progression …

BACKGROUND/PURPOSE: The efficacy and safety of chemotherapy as third-or higher-line
therapy for advanced non-small cell lung cancer (NSCLC) are unclear. The purpose of this …

7590 Background: Pemetrexed (Pem) 500 mg/m2 (Pem 500) is currently the standard
treatment for pts with locally advanced or metastatic NSCLC who had prior chemotherapy. In …

Purpose This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib
in patients with advanced non-small cell lung cancer (NSCLC) previously treated with …

NSCLC accounts for 80% of all cases of lung cancer, which is the leading cause of cancer
mortality. The majority of NSCLC patients present with advanced, unresectable disease …